Delix Therapeutics has raised $100 million in an oversubscribed Series C financing to advance a new class of neuroscience medicines designed to promote brain-cell connectivity without producing the hallucinatory effects associated with traditional psychedelics. Announced on November 9, 2026, the round was co-led by Johnson & Johnson Innovation, through its corporate venture capital organisation JJDC, and SV Health Investors’ Dementia Discovery Fund. Existing investors RA Capital, UC Investments, Artis Ventures, OMX Ventures, Dolby Family Ventures and Bail Capital participated, alongside new investors including Adage Capital Management, Hamilton Square Partners Management, Vestal Point Capital and YK Bioventures. Based in Bedford, Massachusetts, Delix is developing a pipeline of medicines called neuroplastogens, with its lead candidate, zalsupindole (DLX-001), being developed for recurrent major depressive disorder. The new funding will support its progression towards Phase IIb clinical development, while providing capital for additional neurological and neurodegenerative disease programmes. The investment marks an important transition for the company from early clinical research towards larger-scale testing of its differentiated neuroscience platform.

Why Neuroplastogens Represent a Different Approach to Brain Treatment
Many existing treatments for depression work by influencing the chemical signalling systems involved in mood and emotional regulation. Some established medicines require regular administration over extended periods before patients experience meaningful improvements. Psychedelic compounds have generated scientific interest because they may produce changes in neural connectivity and plasticity, but traditional psychedelic treatments can involve hallucinations, intensive supervision and controlled clinical settings. Neuroplastogens are being developed around a different idea: encouraging the brain to form and strengthen connections between neurons without necessarily producing the perceptual effects associated with psychedelic drugs. Delix is attempting to separate the biological processes linked to neuroplasticity from the hallucinatory properties of the compounds that inspired its research. The scientific goal is to develop medicines that can support structural and functional changes in selected neural circuits while remaining suitable for more conventional outpatient treatment. This could create a new direction in neuroscience drug development, although the therapeutic benefits and long-term safety of individual neuroplastogens still need to be established through appropriately designed clinical trials.
Zalsupindole Is Delix’s Lead Candidate for Major Depressive Disorder
The main asset supported by the Series C is zalsupindole, also known as DLX-001. It is an orally available investigational neuroplastogen inspired by 5-MeO-DMT, a psychedelic compound also known as mebufotenin. Delix has engineered the molecule with the aim of promoting structural and functional neuroplasticity without the hallucinatory, dissociative or sedative effects associated with some psychedelic and dissociative treatments. The proposed mechanism focuses on improving the brain’s ability to form and maintain connections between neurons, particularly within circuits relevant to psychiatric conditions. The company is initially developing zalsupindole for recurrent major depressive disorder, where patients may continue to experience symptoms despite existing treatments. Its potential advantage would be a treatment that produces meaningful biological changes without requiring the prolonged supervised sessions associated with some traditional psychedelic therapies. However, zalsupindole remains an investigational medicine. Its proposed advantages must be tested in larger controlled trials before conclusions can be drawn about its effectiveness, safety or suitability for routine clinical use.
Early Phase Ib Results Provide the Basis for Further Clinical Testing
Delix reported encouraging preliminary findings from a Phase Ib study involving 18 adults with major depressive disorder. Participants received either daily dosing over seven consecutive days or two doses during the first week. According to the company’s results, both groups experienced an approximately 50% mean reduction in Montgomery-Åsberg Depression Rating Scale scores at Day 8 compared with baseline. The reported improvement remained through Day 36, four weeks after the final dose. The company also reported that no serious adverse events occurred and that no hallucinatory or dissociative effects were observed in this small study. These findings are an early clinical signal, not proof that zalsupindole is an effective treatment. The study was small and its results require confirmation in a larger, placebo-controlled trial. Delix has also reported a favourable safety and tolerability profile across more than 120 participants studied to date, but that broader exposure should not be confused with the number of patients in the Phase Ib depression study. The important next step is determining whether the preliminary results can be reproduced under more rigorous clinical conditions.

The Planned Phase IIb Trial Will Test Whether the Early Results Hold Up
The Series C will help Delix advance zalsupindole into a Phase IIb proof-of-concept study for recurrent major depressive disorder. The company expects to initiate the trial in the first half of 2027. The proposed study is randomised, double-blind and placebo-controlled, meaning participants are assigned to different treatment groups and neither patients nor investigators know the treatment allocation during the trial. The U.S. Food and Drug Administration cleared the investigational new drug application and proposed Phase II trial design in October 2025, including a protocol that permits at-home self-administration. This is an important regulatory milestone, but it does not mean that the FDA has approved zalsupindole as a medicine. The next trial will need to assess whether improvements are greater than placebo, how long any benefits last, what dosing approach works best and whether the safety profile remains acceptable with a larger patient population. The possibility of a take-home treatment is commercially significant because it could reduce the logistical demands associated with clinic-based psychedelic therapies if later studies establish that it can be used safely and effectively.
Delix Is Building a Broader Pipeline Beyond Depression
Although zalsupindole is the most advanced programme, Delix is developing additional neuroplastogens for a broader group of psychiatric, neurological and neurodegenerative conditions. The company is investing in compounds designed to influence neural connectivity across different disease pathways, rather than depending on a single drug candidate or indication. Its research includes preclinical work involving neurodegenerative conditions such as Alzheimer’s and Parkinson’s diseases. Delix and its investors have highlighted findings involving increased synaptic density across several preclinical models, suggesting possible opportunities beyond depression. These results remain at the preclinical research stage and should not be interpreted as evidence that the compounds treat Alzheimer’s or Parkinson’s in humans. The new financing is expected to support additional development candidates, IND-enabling studies and the progression of selected programmes towards clinical evaluation. This multi-asset strategy could help Delix build a broader neuroscience portfolio if the underlying biology translates across diseases, but each candidate and indication will require its own safety and efficacy evidence.
Why Johnson & Johnson and Specialist Biotech Investors Are Backing Delix
The investor group behind the $100 million Series C brings together pharmaceutical expertise, neuroscience investment experience and existing support for the company. Johnson & Johnson Innovation’s JJDC provides a corporate venture investment connection to a major pharmaceutical business, while the Dementia Discovery Fund brings specialist experience in neurodegenerative disease research. UC Investments and UC Davis Health Ventures also have a connection to Delix through its research origins at the University of California, Davis. The company’s scientific foundation includes work by David Olson, a UC Davis professor of chemistry and Delix co-founder, whose laboratory research helped establish the science behind neuroplasticity-promoting compounds. Mark Rus leads the company as CEO, while Nick Haft is another co-founder and serves on its board. For investors, the opportunity is to help translate an emerging scientific concept into a clinical-stage drug platform. The risks are equally significant: neuroscience drug development is expensive, clinical outcomes can differ from early signals, and promising mechanisms do not always lead to approved medicines. The Series C provides the capital required to move the science through these demanding development milestones.
What Delix’s 0M Series C Means for the Future of Neuroscience
Delix Therapeutics’ latest financing highlights investor interest in medicines that aim to improve brain function through neuroplasticity while avoiding some of the practical limitations associated with traditional psychedelic treatments. Its approach combines medicinal chemistry, neuroscience research and a pipeline strategy that extends from depression into other neurological and neurodegenerative conditions. The immediate test is zalsupindole: whether its early clinical signals can be reproduced in a larger placebo-controlled Phase IIb study and whether an at-home treatment model can demonstrate an acceptable safety profile. Beyond that, Delix will need to show that its neuroplastogen platform can generate additional drug candidates with distinct and clinically meaningful benefits. None of the company’s investigational compounds should be treated as established therapies, and the Phase Ib findings do not establish long-term efficacy. The $100 million Series C gives Delix substantial resources to pursue the next stage of clinical development. Its progress could help determine whether non-hallucinogenic neuroplastogens become a meaningful new category in neuroscience medicine or remain an interesting but unproven area of research.
Sources
- Delix Therapeutics – Official $100M Series C announcement, November 9, 2026
- UC Davis – Series C investment and Zalsupindole Phase IIb development, November 10, 2026
- Delix Therapeutics – Phase Ib results and FDA-cleared Phase II trial design, October 28, 2025
- Delix Therapeutics – Leadership and scientific team
- Delix Therapeutics – History and neuroplastogen research
- Fierce Biotech – Delix’s $100M financing and clinical development strategy
- Goodwin – Legal confirmation of the $100M Series C and investors